Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of ...

Unlike the HeLa cell line named after her, Henrietta Lacks was little heard of until the 2010 publication of Rebecca Skloot’s book, The Immortal Life of Henrietta Lacks. Born in 1920 in Virginia, ...

In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...

This valuable study on strategies used by Pseudomonas to subvert hots immunity identifies a new immune evasion strategy. The study presents solid evidence on the cleavage of VgrG2B by Caspase 11 and ...